Several real-world studies [26–31] demonstrated the percentage of adjuvant target therapy based on trastuzumab-containing regimens ranged from 65.6 to 88.8% among HER2 + breast cancer patients in the US. This evidence concerns the gene ERBB2 and breast carcinoma.